The actions of the following pressurized bronchodilators were compared by administration to 24 asthmatics: (1) Medihaler Iso Forte, (2) Alupent, (3) Medihaler-duo, (4) Bronchilator, and (5) Prenomiser Plus. These contained one or more of the following: isoprenaline, orciprenaline, isoetharine, phenylephrine, atropine methonitrate, and thenyldiamine. The dose was a single discharge from the container. The response was assessed by calculating the mean percentage change in F.E.V. at intervals after inhalation.
duration of response. Consequently, the various results are not strictly comparable and no very clear picture emerges regarding the relative merits of the various drugs and their marketed preparations.
In an attempt to resolve the confusion of choice arising from this situation, we selected five pressurized aerosols for comparative trial. The preparations were Medihaler IsoForte,Medihalerduo, Bronchilator, Prenomiser Plus, and Alupent. Table I shows their composition and the dose of each component drug in micrograms delivered by a single discharge from the container as stated by the manufacturers.' They were tested with the following criteria in view: 1. Potency of bronchodilator activity, i.e., amplitude of maximum response 2. Time taken to reach maximum response 3. Extent to which differences in bronchodilator activity can be ascribed to differences in dosage 4. Duration of effect 5. Influence of adjuvant substances 6. Incidence of rebound bronchoconstriction 7. Absence of response to propellent.
The introduction of isoprenaline marked an important advance on adrenaline, since it acts exclusively on al-receptors. However, it increases the force and frequency of the heart-beat and dilates blood-vessels in skeletal muscle, and hence may cause palpitations, headache, and hypotension. More recently, the occurrence of occasional dangerous cardiovascular effects has been suspected (Lockett, 1965; Greenberg and Pines, 1967, and subsequent correspondence; Speizer, Doll, Heaf, and Strang, 1968) .
Isoetharine was found by animal experiment to protect guinea-pigs from histamine-induced bronchospasm (Siegmund, Granger, and Lands, 1947) . Its cardiovascular effects were found to be smaller than those of isoprenaline (Lands, Luduena, Grant, and Ananenko, 1950) . It was introduced ino clinical practice by Hersohfus, Bresnick, Levinson, and Segal (1951) , who on a weight-for-weight basis found it to have approximately one-third of the bronchodilator effect of isoprenaline.
Orciprenaline was also found by animal experiment to exert a smaller cardiovascular effect and 1 The dose is estimated by the manufacturer in the following way.
The concentration of drug in the suspension is assayed chemically. A batch of valves is sampled statistically, and the volume of the valve-chamber checked. The proportion of the discharged dose which is retained by the apparatus is measured. The dose delivered is the amount discharged less the amount retained in the apparatus a more persistent bronchodilator effect than isoprenaline (Engelhardt, Hoefke, and Wick, 1961) , and it was introduced into clinical practice by Spitzbarth and Albers (1961) .
Phenylephrine, present in Medihaler-duo and in Bronchilator, is a sympathomimetic amine acting on a-receptors. Its function is to cause vasoconstriction in the bronchial mucosa, delay absorption of the bronchodilator, and so prolong its duration of effect. That such prolongation may occur has been demonstrated by Kall6s and Kall6s-Deffner (1964) in histamine-induced bronchospasm, and by Cohen and Hale (1965) in chronic bronchitis and pulmonary emphysema, though Mattila and Muittari (1966) didnotachieve this result. Phenylephrine might also have a slight indirect bronchodilator effect by constricting mucosal blood-vessels whose engorgement contributes to airway narrowing. Goldfarb and Romanoff (1962) obtained evidence of bronchodilator action from phenylephrine alone.
Atropine methonitrate causes bronchodilatation more slowly but more persistently than does isoprenaline. When given together with isoprenaline the actions are additive (Capel and Fletcher, 1964) and the effect is that of prolonging the bronchodilatation initiated by the isoprenaline (Chamberlain et al., 1962) . Its mode of action is presumably by the reduction of vagally mediated bronchoconstrictor tone. It reverses bronchoconstriction caused by inhalation of various dusts (Dautrebande, Lovejoy, and McCredie, 1962; Widdicombe, Kent, and Nadel, 1962) and by hypoxia (Astin and Penman, 1967) .
Thenyldiamine is an antihistamine. Although antihistamines relieve histamine-induced bronchospasm (Altounyan, 1964) , their effect in naturally occurring asthma is dubious.
METHOD
The preparations were given to 24 asthmatic subjects, 18 men and 6 women. The age range was 19 to 70 (mean 43 2) years. The diagnostic criteria were those of Scadding (1963) . Excluded from the trial were patients suffering from chronic bronchitis-namely, those producing sputum on most days for at least three months in the year and for at least two years, those prone to recurrent chest infections, and those whose airway obstruction did not vary in severity over short periods of time. Tests were undertaken when the patients were in a steady state of moderate bronchospasm as estimated clinically and by comparison of the forced expiratory volume in one second (F.E.V.) with each patient's expected value. The pretreatment F.E.V. was expressed as a percentage of the expected F.E.V. for each patient. The mean of (Friedman, 1937) . Mushin (1967) has drawn attention to the need to continue a test for at least half an hour when measuring the maximum response to a bronchodilator. By testing for a longer period we have shown that about one patient in eight achieved a maximum response one hour after inhalation. We think we can assume that the adjuvant drugs in these preparations (phenylephrine in Medihaler-duo and atropine in Prenomiser Plus) were exerting negligible bronchodilatation at the early stage (Table Ill) at which the maximal responses were obtained, and hence that these values were solely the effect of isoprenaline. Figure 2 shows the mean maximum percentage increase in F.E.V. produced by these preparations plotted against the logarithm of the dose of isoprenaline in micrograms (solid circles). The points lie close to a straight line fitted by least squares. useful, as there will be individual differences depending on the initial level and on the improvement demanded by the circumstances pertaining at the time. Most physicians will probably agree that an increase in F.E.V. of less than 10% is valueless, and that patients are more likely to be aware of useful improvement when the F.E.V. has increased by 20 % to 30 %. Table V shows the times after inhalation of single doses of each preparation during which the mean F.E.V. was raised by 20% and 30%. THE EFFECT OF PROPELLENT In order to check that the freon propellent was devoid of activity on the bronchi, nine patients were given inhalations of propellent alone from containers which were indistinguishable from those containing bronchodilator. The changes that occurred during the three hours after inhalation of propellent were small, showing apparently random rises and falls. The mean changes in F.E.V. from basal levels lay between -3-6% and +8-1%. These were comparable to those obtained by Edwards (1964 ), El-Shaboury (1964 , Jacobsen and Prime (1965) , Kennedy (1965 ), Hoffbrand et al. (1966 , and Mattila and Muittari (1966 There were no material differences in the time of occurrence of the negative phases: the bulk of the negative phases occurred between 90 and 180 minutes. A few occurred after that time, up to five hours, but the numbers were few and some patients who suffered rebound bronchoconstriction withdrew at an earlier stage. Hence, there are no useful data about the incidence at a very late stage. Only two patients had negative phases after Medihaler Iso Forte, compared with four or five with the other preparations. The total incidence of negative phases in the 92 experiments was 21 (23%). There were three patients whose F.E.V. fell to 40% below -basal and two to 50%, but the numbers are too small to implicate the preparations that were used.
As there was a very low incidence of rebound bronchoconstriction occurring soon after inhala- (Fig. 4) The percentage increase over basal is most commonly used as a measure of bronchodilator effectiveness, and this tradition has been followed in this paper. There are, however, theoretical disadvantages to the use of the percentage increase which we propose to discuss elsewhere (see also Feinmann and Newell (1963) ). One major drawback is that the distribution of this statistic tends to be positively skewed, so that the arithmetical mean is at the mercy of a few high readings. This is evidenced by the fact that the mean F.E.V. is considerably greater than the median F.E.V. for some preparations, especially around the time of maximum response. The best method of assessing duration of effect also requires further study.
There is evidence to suggest that bronchitics may respond better than asthmatics to atropine. Altounyan (1964) 
